Voyager Therapeutics (VYGR) Operating Expenses (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Operating Expenses data on file, last reported at $32.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 20.17% year-over-year to $32.9 million; the trailing twelve-month figure through Mar 2026 stood at $163.9 million (down 2.87% YoY), and the FY2025 full-year result was $172.2 million, up 5.47% from the prior year.
• Operating Expenses fell to $32.9 million in Q1 2026, from $45.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $45.3 million in Q4 2025 to a low of $20.1 million in Q2 2022.
• A 5-year average of $34.6 million and a median of $35.7 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses slumped 32.94% in 2022 and surged 56.42% in 2023, its largest moves.
• Tracing VYGR's Operating Expenses over 5 years: stood at $23.0 million in 2022, then surged by 56.42% to $36.0 million in 2023, then grew by 23.83% to $44.6 million in 2024, then gained by 1.55% to $45.3 million in 2025, then dropped by 27.4% to $32.9 million in 2026.
• Business Quant data shows VYGR's Operating Expenses at $32.9 million in Q1 2026, $45.3 million in Q4 2025, and $44.0 million in Q3 2025.